Connect® MM- The Multiple Myeloma Disease Registry

Inclusion Criteria:

Cohort 1 and 2

* Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
* Age ≥18 years
* Willing and able to provide signed informed consent
* Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Cohort 3

* Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
* Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
* Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.

Exclusion Criteria:

Cohort 1 and 2

- None

Cohort 3

* Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
* Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
* Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsored registry could be considered for enrollment in Cohort 3, if inclusion and exclusion criteria are met.
* Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified